Why the study?
Does cardiac AAV6-betaARKct gene therapy improve cardiac function and remodeling in chronic heart failure?
Population
Chronic heart failure
Comparison
Cardiac AAV6-betaARKct gene therapy vs Beta-blocker alone
Design
Preclinical
Follow-up
Long-term
Authors
Loading...
Hypothesis-generating for AAV6-betaARKct in animal HF models; human trials needed before any clinical consideration.
Does cardiac AAV6-betaARKct gene therapy improve cardiac function and remodeling in chronic heart failure?
AAV6-betaARKct gene therapy improves cardiac function and reverses remodeling in chronic heart failure, showing potential long-term therapeutic value.
Rengo et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: